PDOX News

20
Nov

NOV 19, 2017: Certis Oncology Roundtable: The Paradigm Needs to Be Changed

Fritz Eilber, MD and Arun Singh, MD chat with UCLA oncology patient Rachel Young Huff about the research opportunity for PDOX mouse models.

24
Oct

OCT 24, 2017: Certis Oncology Roundtable: It’s About People

Fritz Eilber, MD and Arun Singh, MD chat with UCLA oncology patient Rachel Young Huff about her PDOX mouse models.

1
Sep

SEPT 1, 2017: In Memory of Rachel Young Huff

Last week we lost a beloved member of the Certis Oncology family. As she participated in our research,Rachel became our close friend. She inspired us with her uncommon bravery, her ironic sense of humor, her vitality and her brilliant life energy. She leaves behind her husband Forrest, two beautiful children, a large extended family and a loving community.  When we remember Rachel, we’ll

Read more

29
Aug

Open House at Certis Oncology! Friday September 8th, 12 noon

2
Aug

AUG 2, 2017: UCLA study provides roadmap to more personalized treatment for soft tissue sarcoma and other aggressive cancers

PDOX has long shown great promise in modeling how sarcoma and other cancers can respond to and resist therapies. A new UCLA study, published in JCO Precision Oncology, is the first to identify patient and tumor characteristics that predict the successful creation of PDOX models and which types of sarcomas are most likely to grow as xenografts. The research, which

Read more

2
Aug

AUG 2, 2017: Certis Oncology: A Patient’s Story

Rachel — a wife, mother of two, and career woman — chats candidly about her oncology journey at UCLA: “If I didn’t have these mice, I wouldn’t know which drugs work on me.”

13
May

UCLA’S DR. FRITZ EILBER DISCUSSES HIS WORK WITH SARCOMA PATIENTS AND HIGHLIGHTS THE URGENCY OF FINDING THE RIGHT TREATMENT FOR EACH PATIENT.

Two landmark studies are now underway to determine if treatment can benefit the patient after only one cycle. Watch Here

18
Mar

MARCH 18, 2017: SSO 2017 ANNUAL CANCER SYMPOSIUM/SEATTLE

Session #70: Tumor Grade & Preoperative Therapy Impact the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX): UCLA Sarcoma Program Prospective Clinical Trial By Dr. Tara Russell, M.D. Research Fellow/Surgical Resident UCLA Department of Surgical Oncology-1:30 p.m., Room 6A Abstract [pdf] | Given the diverse and often aggressive nature of soft tissue sarcomas (STS), there is a need for more

Read more

9
Mar

MARCH 9, 2017: CANCER FORUM/MUSCULOSKELETAL RESEARCH GROUP TUMOR BOARD PRESENTATION AT UCLA

Cancer Forum/Musculoskeletal Research Group Tumor Board presentation at UCLA     “Tumor Grade & Neoadjuvant Therapy Impact The Establishment of Soft-Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX): A UCLA Sarcoma Program Prospective Clinical Trial” By Tara Russell, M.D. Research Follow/Surgical Resident UCLA Department of Surgical Oncology 3:30 p.m., SM UCLA Conference Room #3 Objective: Feasibility of Personalized Oncology Care in Sarcoma

Read more

9
Nov

NOVEMBER 9, 2016: CONNECTIVE TISSUE ONCOLOGY SOCIETY (CTOS), LISBON, PORTUGAL

“Factors Impacting the Establishment of Individual Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX) Mouse Models: A UCLA Sarcoma Program Prospective Clinical Trial” by Eckardt et al. By Tara Russell, MD, MPH UCLA General Surgery Resident This study demonstrates a very high (82%) establishment rate for PDOX in HG-STS patients who were treatment naïve at the time of surgical excision. Learn

Read more